The efficacy of remaxol as a hepatoprotective agent in long-term psychopharmacotherapy

• Published in: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova Vol. 119; no. 4; p. 43
• Main Authors: Filippova, N V, Barylnik, Yu B, Shuldyakov, A A
• Format: Journal Article
• Language: Russian
• Published: Russia (Federation) 2019
• Subjects: remaxol; psychopharmacotherapy; hepatoprotectors; neuroleptics
• ISSN: 1997-7298
• DOI: 10.17116/jnevro201911901143

Evaluation of the efficacy of psychopharmacotherapy with the hepatoprotector remaxol. A study was conducted on 60 male patients diagnosed with 'Paranoid schizophrenia, continuous progression type course' who received therapy for the underlying disease with traditional antipsychotics in a psychiatric inpatient setting. During the 12 days of the study, 30 patients (main group) received neuroleptic therapy in combination with intravenous infusions of remaxol (400.0 ml), the remaining 30 patients (control group) received 'active placebo' (0.9% sodium chloride solution, 400.0 ml). A decrease in the frequency and severity of astheno-vegetative, dyspeptic, hemorrhagic, cholestatic syndromes and hepatomegaly was shown. The absence of side-effects along with an improvement in the general well-being of the patients is extremely important in long-term psychopharmacotherapy of psychiatric patients.